Doctors say HPV vaccine should be given to everyone

	Tweet

A new vaccine which will protect women against four types of the human papillomavirus (HPV) known to cause cervical cancer will be available within weeks in the UK.

The vaccine provides protection against four types of HPV or human wart virus and is aimed at stopping the spread of the virus.

Experts want all women between the ages of nine and 55 to receive jabs against the disease, with an annual programme set up to vaccinate adolescents in schools and say it should be given to girls before they become sexually active to maximise their protection.

But already some are saying the vaccine should be given to both sexes as men can pass on the virus to their sexual partners.

The vaccine Gardasil, was licensed in June by the U.S. Food and Drug Administration for use in women and girls 9 to 26 years of age.

A government advisory committee has also recommended the vaccine for women who have had abnormal pap smears, genital warts or certain other conditions.

However Dr. Bradley Monk, associate professor in gynecologic oncology at the University of California at Irvine, says the vaccine should be a universal vaccine and given to girls and boys and all women and men, regardless of their individual risk factors.

But some groups in the U.S. are opposing mandatory shots for school children and say parents should decide whether to immunize their children against a sexually transmitted virus and believe the vaccine will encourage promiscuity.

Dr. Monk dismisses that argument completely and says that to not use a vaccine which prevents cancer would be one of the greatest tragedies.

The virus which can also cause cancer of the penis is responsible for as many as 3,000 cases of cervical cancer in Britain each year.

Gardasil which is manufactured by drug company Merck has been found to be 100 per cent effective against the two main strains of the virus which trigger most cervical cancers.

Gardasil, has received a green light from the Committee for Medicinal Products for Human Use just seven months after applying for a licence and the European Commission is now expected to grant an authorisation for marketing by September.

The decision by the European medicines watchdog will increase pressure for a mass vaccination programme to be brought in by the end of the year.

Experts want all women between the ages of nine and 55 to receive jabs against the disease, with an annual programme set up to vaccinate adolescents in schools.

Such a programme could reduce the need for smear tests - and significantly reduce the incidence of the cancer, which kills 1,000 British women each year.

The cost of the vaccine is expected to cost around £60 per dose, with patients needing three treatments.

RELATED STORIES:
Scientists identify how virus triggers cervical and mouth cancer   Staging of cervical cancer complicating pregnancy   Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia   Vaccine no replacement for Pap test   The Pill doesn’t affect cervical pre-cancer risk   Phenoxodiol Produces Anti-cancer Responses in Women with Cervical Cancer   Newly Created Cancer Stem Cells Could Aid Breast Cancer Research   $11.5 Million Cervical Cancer Grant Awarded to UAB Cancer Center, Partners   Cervical cancer vaccine can protect men from HPV   Virus causes rare form of cervical cancer too   A Cervical Cancer Screening Month Resolution   US FDA approves Hycamtin for cervical cancer   Study indicates vaccine prevents cervical cancer   Newer cervical cancer test no better than the old?   High HPV Concentrations, Smoking Significantly Raise Risks of Cancer   Screening for cervical cancer low for immigrant women   New cervical cancer test increases the detection rate of abnormal cells   Smoking raises virus-related cervical cancer risk   Good results with cervical cancer vaccine in young girls   Cervical cancer vaccine gives long protection   Merck’s cervical cancer vaccine on sale in Europe   Study determines costs of breast and cervical cancer detection among low-income women

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]